Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 17/20 | 0.53 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.52 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | CDK9 | P50750 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12485572 | 0.90 | CCNT1 (0.54) | SCN9ACCNT1CCNE2CCNE1CDK2 | |
| SCHEMBL12487181 | 0.89 | USP2 (0.47) | SCN9ACCNT1CCNE2CCNE1CDK2 | |
| SCHEMBL12487113 | 0.89 | CDK2 (0.53) | SCN9ACCNT1CCNE2CCNE1CDK2 | |
| SCHEMBL12485723 | 0.88 | CA12 (0.52) | SCN9ACCNT1CCNE2CCNE1CDK2 | |
| SCHEMBL12486402 | 0.88 | CCNT1 (0.49) | SCN9ACCNT1CCNE2CCNE1CDK2 | |
| SCHEMBL12486627 | 0.86 | CCNT1 (0.50) | SCN9ACCNT1CCNE2CCNE1CDK2 | |
| SCHEMBL12486620 | 0.84 | SCN9A (0.67) | SCN9A | |
| SCHEMBL12487169 | 0.83 | SCN9A (0.51) | SCN9ACCNT1CCNE2CCNE1CDK2 | |
| SCHEMBL12485374 | 0.82 | SCN9A (0.48) | SCN9ACCNT1CCNE2CCNE1CDK2 | |
| SCHEMBL12486441 | 0.82 | SCN9A (0.48) | SCN9ACCNT1CCNE2CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9226929-B2 | Pharmaceutically active disubstituted triazine derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-05 | — | — | US | claimed |
| US-20140179662-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2014-06-26 | — | — | US | claimed |
| CN-103582482-A | Pharmaceutically active disubstituted triazine derivatives | LEAD DISCOVERY CENTER GMBH | 2014-02-12 | — | — | CN | claimed |
| US-9226929-B2 | Pharmaceutically active disubstituted triazine derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-05 | — | — | US | disclosed |
| US-9226929-B2 | Pharmaceutically active disubstituted triazine derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-05 | — | — | US | disclosed |
| US-9226929-B2 | Pharmaceutically active disubstituted triazine derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-05 | — | — | US | disclosed |
| US-20140179662-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2014-06-26 | — | — | US | disclosed |
| US-20140179662-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2014-06-26 | — | — | US | disclosed |
| US-20140179662-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2014-06-26 | — | — | US | disclosed |
| EP-2680852-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | Lead Discovery Center GmbH (DE) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012117048-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2012-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179662-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | PDE5A, TESK2, PAK5 | SCN9A 4613/4885CCNT1 3922/4885CCNE2 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.